Traders should monitor for upcoming regulatory interactions and potential pre-NDA feedback from the FDA; the strong clinical data significantly de-risk development and may catalyze investor interest ahead of the mid-2026 submission.
Price Chart
Executive Summary
Monopar Therapeutics announced positive Phase 3 FoCus trial results for ALXN1840 in Wilson disease patients with neurologic symptoms, showing superior neurologic improvement and less worsening versus standard of care. The data support an NDA submission planned for mid-2026, marking a key regulatory milestone for this first-in-class therapy.
Key Facts
- ALXN1840 demonstrated 9% rate of neurologic worsening vs 25% on standard of care at Week 48 (p=0.038)
- 45% of ALXN1840-treated patients showed clinically meaningful neurologic improvement vs 32% on standard of care
- CGI-S and CGI-I improvements were significantly greater with ALXN1840 (p=0.008 and p=0.003, respectively)
- Durable benefit observed over ~3 years of follow-up with a favorable safety profile
- NDA submission for ALXN1840 planned for mid-2026
Financial Impact
High potential value inflection given the rare disease indication and lack of effective neurologic treatments in Wilson disease; supports near-term regulatory filing and increases probability of approval
Risk Factors
- Regulatory uncertainty: FDA may require additional data or raise safety concerns despite positive trial results
- Commercialization risk: Limited market size for Wilson disease and potential competition from existing chelation therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276675 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers